Company Shilpa Medicare Limited

Company Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Equities

SHILPAMED

INE790G01031

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:49 26/04/2024 pm IST			5-day change	1st Jan Change
545.5 ^INR	+2.86%		+2.05%	+65.10%

18/04	Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	MT
17/04	Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	MT

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.

Number of employees: 1,179

INR in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Product and Services 99.2 %	11,354	99.1 %	10,415	99.2 %	-8.27%
Others 0.6 %	55	0.5 %	67	0.6 %	+21.79%
Power 0.2 %	46	0.4 %	19	0.2 %	-58.53%

INR in Million	2022	Weight	2023	Weight	Delta
India 48.6 %	4,880	42.6 %	5,106	48.6 %	+4.62%
Europe 20.3 %	3,252	28.4 %	2,131	20.3 %	-34.46%
United States 15.6 %	1,910	16.7 %	1,639	15.6 %	-14.16%
Rest of World 15.5 %	1,414	12.3 %	1,625	15.5 %	+14.94%

Managers	Title	Age	Since
Vishnukanth Bhutada Chaturbhuj CEO	Chief Executive Officer	63	20/87/20
Alpesh Dalal DFI	Director of Finance/CFO	-	31/21/31
Ganeshchandra Sonavane CTO	Chief Tech/Sci/R&D Officer	-	-
Krishnappayya Desai CMP	Compliance Officer	-	16/22/16
Sharath Reddy Kalakota COO	Chief Operating Officer	58	01/91/01
Ritu Tiwary CMP	Compliance Officer	47	23/22/23
R. K. Somani PRN	Corporate Officer/Principal	-	-
Awez Pathan PRN	Corporate Officer/Principal	55	-
Seshachalam Unnam PRN	Corporate Officer/Principal	59	03/08/03
Rajyashri Karur Ramakrishnan PRN	Corporate Officer/Principal	60	01/18/01

Members of the board	Title	Age	Since
Vishnukanth Bhutada Chaturbhuj CEO	Chief Executive Officer	63	20/87/20
Hetal Madhukant Gandhi BRD	Director/Board Member	58	02/21/02
Arvind Vasudeva BRD	Director/Board Member	63	02/21/02
Kamal Kishore Sharma BRD	Director/Board Member	76	01/22/01
Omprakash Tulsiram Inani CHM	Chairman	67	23/88/23
Sharath Reddy Kalakota COO	Chief Operating Officer	58	01/91/01
Anita Bandyopadhyay BRD	Director/Board Member	55	11/22/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	97,790,908	38,408,541 ( 39.28 %)	0	39.28 %

Name	Equities	%	Valuation
Vishnukanth Bhutada Chaturbhuj 7.333 %	6,365,610	7.333 %	35 M ₹
Dharmavati Bhutada 7.152 %	6,207,796	7.152 %	34 M ₹
Ravi Inani 4.616 %	4,006,370	4.616 %	22 M ₹
Suraj Kumar Inani 4.586 %	3,980,695	4.586 %	22 M ₹
Ta Fii Investors Ltd. 3.485 %	3,025,000	3.485 %	17 M ₹
Omprakash Tulsiram Inani 3.304 %	2,867,691	3.304 %	16 M ₹
Deepak Kumar Inani 3.150 %	2,733,960	3.150 %	15 M ₹
Kanta Devi Inani 2.926 %	2,540,096	2.926 %	14 M ₹
Pivotal Enterprises Pvt Ltd. 2.535 %	2,200,000	2.535 %	12 M ₹
Keshav Bhutada 2.304 %	2,000,000	2.304 %	11 M ₹

Shilpa Medicare Ltd.

Shilpa House Hyderabad Road

584135, Raichur

+91 85 3223 8704

http://www.vbshilpa.com

address Shilpa Medicare Limited(SHILPAMED)

Name	Category and Sector
FTF Pharma Pvt Ltd. FTF Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology FTF Pharma Pvt Ltd. engages in the provision of pharmaceutical services. It offers identification of products, regulatory strategy, non-infringing and IP strategy, and bioequivalence and clinical trials. The company was founded by Jayanta Kumar Mandal on June 20, 2012 and is headquartered in Ahmedabad, India.	Pharmaceuticals: Major
Shilpa Biocare Pvt Ltd.
Shilpa Pharma Lifesciences Ltd. Shilpa Pharma Lifesciences Ltd. Pharmaceuticals: MajorHealth Technology Part of Shilpa Medicare Ltd., Shilpa Pharma Lifesciences Ltd. is an Indian company that manufactures pharmaceutical products. The private company is based in Raichur, India. The company was founded in 2020. Santosh Kumar Mahil has been the CEO of the company since 2024.	Pharmaceuticals: Major

Company calendar

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+65.10%	568M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals